<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378479</url>
  </required_header>
  <id_info>
    <org_study_id>POSA-FLU</org_study_id>
    <nct_id>NCT03378479</nct_id>
  </id_info>
  <brief_title>Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients</brief_title>
  <acronym>POSA-FLU</acronym>
  <official_title>A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to deliver proof of concept that antifungal prophylaxis can
      reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit)
      patients with severe influenza.

      The investigators will perform an interventional non-blinded randomized controlled
      multicentric proof-of-concept study in patients with severe influenza admitted to the ICU.
      Patients will be randomized to the posaconazole prophylaxis group or to the SOC (standard of
      care) group. Oseltamivir will be started at the discretion of the investigator. Patients in
      the posaconazole group will receive posaconazole prophylaxis for 7 days.

      addendum: pharmacokinetics of posaconazole as prophylaxis for invasive fungal disease on ICU
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critically ill patients with PCR-confirmed influenza criteria) are eligible for inclusion in
      this study and will be randomized to or the posaconazole prophylaxis group or the SOC group.

      If a patient is randomized to the posaconazole prophylaxis group, posaconazole (Noxafil, MSD)
      will be started intravenously from day 1 of randomization (2*300mg( milligram) /d on day 1,
      followed by 1*300mg/d from day 2 for 7 days) In both patient groups (prophylaxis and SOC)
      oseltamivir (non-IMP) will be started at the discretion of the treating physician from the
      first day of ICU admission as 2*150 mg/day for 10 days. If oseltamivir had already been
      started up before ICU admission, oseltamivir treatment will be continued up to a total of 10
      days.

      Within 48 hours after influenza diagnosis a bronchoscopy with BAL (bronchoalveolar lavage)
      and a serum galactomannan will be performed as part of routine ICU care in this type of
      patients. If an IAA-infection is suspected based on the result of this BAL ((A) Aspergillus
      cultured from BAL, or (B) a galactomannan (GM)the patient will be withdrawn from the study
      and antifungal treatment will be started.

      addendum: Extensive PK sampling (UZ Leuven and Radboud): full PK curve on day 2 and day 5
      (predose, 1.5; 2,3,4,6,8,10,12,18,24 h post infusion).

      on non PK days, until day 7, predose sample. PK in BAL fluid only in patients with mechanical
      ventilation and when medically indicated.

      Limited PK sampling: on day 2 and day 5: 1.5-3h, 4-8 h;8-12h; 12-24h post dose. on non PK
      days: PK pre dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of IAA-infection at ICU discharge</measure>
    <time_frame>from date of admission in ICU assessed up to ICU discharge, approximately 21 days</time_frame>
    <description>A patient with IAA-infection is defined as a patient having mycological evidence of Aspergillus and at least one Aspergillus compatible sign or symptom and radiological abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to IAA diagnosis</measure>
    <time_frame>from date of inclusion to date of first sign/symptom of IAA infection, assessed up to ICU discharge, approximately 10 days</time_frame>
    <description>days to IAA diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU stay</measure>
    <time_frame>from date of admission in ICU to date of discharge from ICU, approximately 20 days</time_frame>
    <description>amount of days at ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>from date of admission in hospital to date of discharge from hospital, approximately 25 days</time_frame>
    <description>admission days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>at day 30 and at day 90</time_frame>
    <description>survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identify changes in PK of posaconazole in critically ill patients</measure>
    <time_frame>from day 1 until day 7</time_frame>
    <description>altered clearance of posaconazole in critically ill patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Aspergillosis; Pulmonary, Invasive (Etiology)</condition>
  <arm_group>
    <arm_group_label>SOC + 'Posaconazole 18 MG/ML'</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care treatment for influenza pneumonia (at the investigators discretion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC +Posaconazole 18 MG/ML (milligram/milliliter)</intervention_name>
    <description>.2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days (total 7 days)</description>
    <arm_group_label>SOC + 'Posaconazole 18 MG/ML'</arm_group_label>
    <other_name>Noxafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care (SOC)</intervention_name>
    <description>treatment for influenza pneumonia at the investigators discretion</description>
    <arm_group_label>SOC + 'Posaconazole 18 MG/ML'</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent must be obtained from the patient or his/her legal
             representative prior to any study procedures

          2. Adult patient (≥ 18 years)

          3. PCR-confirmed influenza based on nasopharyngeal swab (NS), bronchial aspirate (BA) or
             broncho-alveolar lavage (BAL) within 7 days before ICU admission or within 48 hours
             after ICU admission. If PCR is not available a positive result of a rapid test is
             required (a negative rapid test does not imply absence of influenza and thus requires
             confirmation by PCR)

          4. Influenza symptoms present for no more than 10 days before ICU admission

          5. Respiratory distress as the main reason for ICU admission. Respiratory distress will
             be defined as tachypnea with an respiratory rate ≥ 25x/min and a paO2/fiO2-ratio
             (fraction of inspired oxygen) ≤ 300 with or without (bilateral) infiltrates.

        Exclusion Criteria:

          1. Patients with age &lt; 18 years

          2. Pregnant women (based on a positive serum sample)

          3. Expected survival on ICU admission ≤ 48h

          4. Patients having influenza symptoms for more than 10 days before ICU admission

          5. Patients being transferred from another hospital ward or another hospital who already
             have mycological evidence for an IAA-infection (based on sputum, BA or BAL culture,
             BAL or serum GM)

          6. Patients with known intolerance or hypersensitivity to posaconazole or other azole
             antifungal agents

          7. Patients that are being treated actively with antifungal agents for invasive
             aspergillosis

          8. Patients with a QTc (corrected QT interval) interval ≥500 msec

          9. Patients with liver cirrhosis (Child C)

         10. Participation in another interventional clinical trial -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost Wauters, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Verweij, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joost Wauters, Phd</last_name>
    <phone>+32 16 344275</phone>
    <email>joost.wauters@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Verweij, Phd</last_name>
    <phone>+31 24 3614356</phone>
    <email>paul.verweij@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bourgeois, Phd</last_name>
      <email>marc.bourgeois@azsintjan.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pieter Depuydt, Phd</last_name>
    </contact>
    <contact_backup>
      <email>pieter.depuydt@uzgent.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Wauters, Phd</last_name>
      <email>joost.wauters@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Greetje A Kampinga, Phd</last_name>
      <email>g.a.kampinga@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Verweij, Phd</last_name>
      <phone>+31-24-3614356</phone>
      <email>Paul.verweij@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MC Erasmus</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bart Rijnders, Phd</last_name>
      <email>b.rijnders@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Joost Wauters, prof. dr.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

